Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767630 | 0.89 | — | — | |
| Formaldehyde SCHEMBL18320449 | 0.83 | — | — | |
| SCHEMBL17513049 | 0.81 | NFKB1 (0.33) | ALDH1A1 | |
| SCHEMBL308608 | 0.78 | — | — | |
| SCHEMBL1057106 | 0.72 | — | — | |
| SCHEMBL12594905 | 0.71 | — | — | |
| SCHEMBL17332077 | 0.69 | — | — | |
| SCHEMBL2860330 | 0.69 | — | — | |
| SCHEMBL17332115 | 0.69 | — | — | |
| SCHEMBL1467337 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122269-A1 | SELECTIVE REDUCTION OF ANTIBODIES | ABBVIE INC (US) | 2025-04-17 | — | — | US | claimed |
| CN-116239754-B | Polyurethane or polyurethane urea aqueous dispersion and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119488608-A | Engineering bispecific antibody coupling drug and preparation method and application thereof | 上海药明合联生物技术有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-119213022-A | Preparation method of antibody-drug conjugate | 上海迈晋生物医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-117838879-B | Preparation method for improving homogeneity of antibody-drug conjugate and application thereof | 上海药明合联生物技术有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20240216521-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN INC (US) | 2024-07-04 | — | — | US | claimed |
| CN-117838879-A | Preparation method for improving homogeneity of antibody-drug conjugate and application thereof | 上海药明合联生物技术有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-11845058-B2 | Cooperative chemical adsorption of acid gases in functionalized metal-organic frameworks | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-19 | — | — | US | claimed |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | IMMUNOGEN, INC. (US) | 2023-12-05 | — | — | US | claimed |
| WO-2023222108-A1 | METHOD FOR PREPARING ANTIBODY-DRUG CONJUGATE | 上海迈晋生物医药科技有限公司 | 2023-11-23 | — | — | WO | claimed |
| CN-114433239-B | Rhodium nanoparticle dispersion and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116239754-A | Polyurethane or polyurethane urea aqueous dispersion and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-114433239-A | Rhodium nanoparticle dispersion and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-113631194-A | Method for preparing cell-binding agent-drug conjugates | 伊缪诺金公司 | 2021-11-09 | — | — | CN | claimed |
| EP-3774880-A1 | SELECTIVE REDUCTION OF ANTIBODIES | AbbVie Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210017222-A1 | SELECTIVE REDUCTION OF ANTIBODIES | ABBVIE INC (US) | 2021-01-21 | — | — | US | claimed |
| US-20200405874-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | claimed |
| WO-2020191306-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| WO-2019191630-A1 | SELECTIVE REDUCTION OF ANTIBODIES | ABBVIE INC. (US) | 2019-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017222-A1 | SELECTIVE REDUCTION OF ANTIBODIES | CD2BP2, CD22, CD2 | ALDH1A1 1260/4885 |
| US-20250122269-A1 | SELECTIVE REDUCTION OF ANTIBODIES | CD2BP2, CD22, CD2 | ALDH1A1 1260/4885 |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | EPCAM, CD2BP2, XPA | ALDH1A1 1529/4885 |
| US-20200405874-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | EPCAM, CD2BP2, XPA | ALDH1A1 1529/4885 |
| US-20240216521-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | EPCAM, CD2BP2, XPA | ALDH1A1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.